



Integrative Approach to Promote Hydroxylations with Novel P450 Enzymes for Industrial Processes



Project acronym: HyPerIn

Project no: EIB.12.026

Prof. Dr. Vlada B. Urlacher

ERA-IB-2 Final conference, Berlin, 16./17.02.2016

Project partners



Prof. Gary Lye



HEINRICH HEINE
UNIVERSITÄT DÜSSELDORF

Prof. Vlada Urlacher



Dr. Andreas Vogel



Prof. Steffen Rupp



Dr. Inger Reidun Aukrust




LABORATORY
of THEORY of
BIOPOLYMERS

Dr. Dominik Gront



Novartis

Dr. Stephan Luetz




- Total project budget: 2024 k€



Introduction


Cytochrome P450 monooxygenases



- Heme *b* containing oxidoreductases
- > 30 types of oxidation reactions
- Hydroxylation of non-activated C-atoms
- Accept a vast variety of substrates

Limitations for application

- Requirement of electron transfer partner(s)
- Limited access to suitable P450 biocatalysts
- Inefficient biotransformation processes




Introduction

- *HyPerIn objectives:*
 - *To provide a platform of novel cytochrome P450 biocatalysts*
 - *To overcome bottlenecks for the application of cytochrome P450 monooxygenases*
- *General project approach:*
 - *Discovery of novel P450s through genome mining*
 - *Construction of designer biocatalysts with optimized P450 systems in recombinant hosts*
 - *Development of a high-throughput platform for P450 biocatalyst evaluation*
 - *Representative process examples at a lab- and a preparative scale*




Technical overview



Technical overview

- *Identification of target compounds and synthesis of reference standards*




Tamoxifen	Amodiaquine	Haloperidol	Ritonavir
Estrogen receptor antagonist	Histamine N-methyltransferase inhibitor	Dopamine receptor inhibitor	HIV-1 protease inhibitor
Breast cancer	Malaria	Psychosis	HIV infection



Technical overview


- *Identification of target compounds and synthesis of reference standards*

Valencene	Grundmann's ketone	Fatty acids
Ingredient of orange peel oil	Precursor for vitamin D3 derivatives	ω -hydroxylation
Grapefruit flavor	Synthesis of medicines	Polymer synthesis



Technical overview

- Development of analytical methods



Technical overview

- *Screening of strains with P450 activity*


Strain		Number of target compound hits					
No.	ID	VAL	AM	HAL	TAM	RIT	GK
1	AAU			1		4	
2	SHR					1	
3	SHY		2	2			
4	SPL	2	3	4	3	9	
5	SER			3		5	
6	TBF		3				1
7	MVI			1	3	1	
8	RST		2	3	2	2	



Technical overview

• DNA-sequencing of strains with P450 activity

I. Sample collection




-Novartis
-c-LEcta

II. Nucleic acid isolation



-DNA
-mRNA

III. Library preparation



-whole genome shotgun
-mate pair
-strand-specific RNA

IV. Sequencing



-Illumina HiSeq2500
-Roche GSjunior

V. Bioinformatic analysis




-assembly
-ORF prediction
-annotation
-gene expression




Technical overview

- DNA-sequencing of strains with P450 activity
- Transcriptomics analysis

Annotation



Genome sizes



108 prokaryotic P450 genes
~ 150 putative redox partners
> 300 eukaryotic P450 genes







Technical overview

- *Establishment of a P450 database*

Internet-based platform:

- *open for partners*
- *~ 53,000 P450-sequences*
- *186 structures*
- *annotation of sequences*
- *structural information*
- *description of domains*
- *available publications*
- *authors and their affiliations*
- *sequential patterns*



http://193.239.206.14/menu_login.php

Database Overview	
	Number of Structures from PDB 186
	Total number of GeneBank records 52711
	Number of novel sequences 71
	Multiple Sequence Alignment Powered by: MUSCLE v3.7 by Robert C. Edgar



Technical overview

- Recombinant expression of P450s in *E. coli*




Concentration of recombinant P450s in *E. coli*: 20 - 400 mg per L culture



Technical overview


- Identification and (co-)expression of appropriate redox partners for P450s

class I



NADH > [FAD] > [2Fe-2S] > [heme]

class III



NAD(P)H > [FAD] > [FMN] > [heme]


Redox partners

YkuN/FdR Pdx/PdR



+

P450 gene of interest

in vitro & *in vivo*







+



Technical overview

- Identification of lead P450 candidates (selected examples)




Technical overview

- *Designer biocatalyst with optimized P450 system expression in host systems*

Optimization of:

- Cell concentration
- Substrate concentration
- Co-solvents
- Redox partners
- Cofactor availability



Technical overview



- *Creation of automated high throughput methods*



Automated platform



HPLC



Technical overview



- *Creation of automated high throughput methods*


Liquid handling arm

Sample and reagent plates

Fermentation plate

Plate reader

Robotic manipulation arm



Disposable tips

Plate carrier

Thermo mixer

Centrifuge


Reagents troughs



Technical overview





- *Optimization of P450 biooxidation processes at μ -scale*



Technical overview



- *Optimization of P450 biooxidation processes at μ -scale*



Summary

- *Start of HyPerIn was delayed*
- *Extension of project duration until 03/2017*
- *Work packages in progress:*
 - *Process scale-up and verification*
 - *Pilot scale production of a fine chemical compound*
 - *Industrial evaluation for a pharma compound*



Novartis



Process design
Scale-up

Preparative
biotransformation


Purification,
structure elucidation,
biological testing



Project outcome



I. A collection of wild-type strains with known P450 activities




II. Genomes of 8 microbial strains with P450 activities are sequenced and annotated

III. More than 450 new P450-genes identified

IV. A new P450 database created




Project outcome



V. A library of novel P450 enzymes expressed in recombinant *E. coli*


VI. A set of recombinant P450-based whole-cell biocatalysts with activity toward target compounds



VII. A high-throughput platform for P450 biocatalyst evaluation at μ -scale



General Evaluation



Acknowledgements

ERA-IB network



National funding organizations



Contact details

*Prof. Dr. Vlada B. Urlacher
Heinrich-Heine University Düsseldorf
Institute of Biochemistry II
Universitätsstraße 1
40225 Düsseldorf*

